Ilika “definite UK interest in alternative battery chemistries and formats” says Baden Hill (LON:IKA)

Ilika plc

Ilika plc (LON:IKA) is the topic of conversation when Baden Hill’s Clean-Tech Equities Specialist Dr Tom McColm caught up with DirectorsTalk for an exclusive interview.

Q1: Tom, Ilika have released an RNS update on Wednesday around their Goliath programme. Can you summarise it for us please?

A1: The company has been working on a 12-month UK government funded project via the Advanced Propulsion Centre – APC – with some automotive scale up specialists called Comau which is part of the blue-chip auto maker Stellantis. The RNS was flagging the conclusion of this project which comprised two main components:

The first component of it was to review and validate the company’s current plan to scale up from its lab scale of 50 kilowatt hours per year to a pre-pilot 2 megawatt hours per year. What the RNS confirmed was the plan had passed muster and they have now begun kit procurement for this scale up which is scheduled to complete and be operational by the end of 2023.

The second component of the project was for Comau to perform an assessment on the company’s Goliath manufacturing processes with respect to their suitability to megawatt scale up and beyond. This was also a success, the RNS pointed out that the processes did prove suitable for scale up and there was an interesting finding that there’s actually a potential benefit compared to tradition lithium-ion production around an accelerated formation stage of the batteries that associated reduced formation time. It meant that the production would be comparatively less capital per kilowatt hour tied up in work in progress.

So, it was overall an announcement of the conclusion of a successfully executed project.


Q2: What’s your take in respect to the company’s business?

A2: One of the things we’ve discussed previously on the company is how far do they intend to take the Goliath part of its business and what are they going to do with it.

What this tells us is the company has raised and is committing the capital to build and prove out Goliath processing in-house up to at least the pre-pilot 2 megawatt hour a year level and possibly beyond.

Q3: Does this affect your view on their business going forward then?

A3: It doesn’t really fundamentally change anything. Their small format Stereax batteries for the medical and IoT applications remain their primary focus and will be their first commercial products to market and will be the things that take them through breakeven and being a proper business.

I think if the in-house Goliath scale up is executed successfully then it will increase the overall value of the business because develop to that stage then the sell-off or spin-off value of that Goliath part of the business will be materially enhanced which is quite an exciting prospect for shareholders.

Q4: What do you assess as the implications with respect to the UK battery sector?

A4: As we said, this was a UK government funded project and the company’s decision to scale up and crack on just shows that there’s definite interest in the UK in alternative battery chemistries and formats to that of the traditional incumbent lithium-ion batteries.

Q5: Does this impact your take on the global battery market more generally?

A5: I would say impact, it basically reinforces it. China dominates the incumbent lithium-ion market and new entrants are always going to struggle, however the supply chain issues and performance limitation in key markets in incumbent lithium-ion batteries are getting worse and there’s no real solutions on the horizon. I’m talking about cobalt, lithium itself etc. so new second generation alternative battery technologies such as solid state lithium, sodium etc. are needed and they will ultimately supplant the incumbent.

So, it really is the place for new entrants to focus, I would say, which is what Ilika and, arguably, the UK are doing.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

10 Top ESG stocks on AIM 2026

These ten AIM-quoted ESG stocks offer investors exposure to companies where commercial progress and responsible business practices go hand in hand.

Ilika starts commercial supply to Cirtec

Ilika begins commercial delivery of Stereax electrodes under first supply order from Cirtec.

Dr Tom McColm on Ilika: Stereax revenues and Goliath milestones (LON:IKA)

Clean-tech equities specialist Dr Tom McColm reviews Ilika’s interim results, highlighting stable cash levels, the first recurring commercial revenues from Stereax, and continued technical and manufacturing progress on the Goliath battery platform.

Ilika CEO Graeme Purdy on Stereax and Goliath progress (LON:IKA)

Graeme Purdy, CEO of Ilika, outlines progress in manufacturing readiness and early customer shipments for the Stereax miniature solid-state battery, as well as ongoing grant-supported development and customer engagement for the Goliath EV battery programme.

Ilika moves into commercial phase with first Stereax electrode order

Ilika has received its first commercial order for Stereax battery electrodes, marking the start of scaled production for medical device applications.

Ilika plc: First Commercial Revenues Signal Pivotal Shift in Solid-State Battery Journey (Video)

Ilika plc has crossed a commercial milestone with its first regular revenue stream from its Stereax battery line, according to Dr Tom McColm of Morphose Capital. With strong cash reserves, momentum on its Goliath platform, and growing interest from defence sectors, the next 12 months could be transformational.

Search

Search